Cargando…
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
Rationale: Prostate cancer (PCa) recurrences after surgery frequently occur. To improve the outcome after surgical resection of the tumor, the theranostic multimodal anti-PSMA targeting agent (111)In-DTPA-D2B-IRDye700DX was developed and characterized for both pre- and intra-operative tumor localiza...
Autores principales: | Lütje, Susanne, Heskamp, Sandra, Franssen, Gerben M., Frielink, Cathelijne, Kip, Annemarie, Hekman, Marlène, Fracasso, Giulio, Colombatti, Marco, Herrmann, Ken, Boerman, Otto C., Gotthardt, Martin, Rijpkema, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6568177/ https://www.ncbi.nlm.nih.gov/pubmed/31244933 http://dx.doi.org/10.7150/thno.35274 |
Ejemplares similares
-
Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023) -
Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2022) -
Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
por: Derks, Yvonne H.W., et al.
Publicado: (2021) -
PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery
por: Derks, Yvonne H.W., et al.
Publicado: (2019) -
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)